Related Experiment Video
Updated: Feb 26, 2026
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
Published on: November 17, 2018
Metabolic, enterohepatic and gut microbial effects of atorvastatin in healthy men
Martin Thomasen1, Maria-Anna Misiakou2,3, Simone S Li2,4
1Center for Clinical Metabolic Research, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, Denmark.
Objective:
Statins are low-density lipoprotein cholesterol-lowering drugs that are highly effective in the prevention of cardiovascular disease and death. Evidence that statin therapy increases the risk of type 2 diabetes is accumulating, but the mechanism behind this phenomenon remains obscure.
Design:
A clinical, randomised, placebo-controlled, double-blind, crossover study.
Methods:
Here, we investigated the effect of atorvastatin on fasting and postprandial circulating concentrations of glucose, gluco-regulatory hormones, bile acid profiles as well as gut microbiota composition. Fifteen healthy men came in for a mixed meal test following 14 days of treatment with atorvastatin (40 mg once-daily during week one and 80 mg once-daily during week two) or placebo.
Results:
Treatment with atorvastatin did not affect postprandial plasma glucose or insulin concentrations, but basal as well as postprandial concentrations of glucagon were increased compared with placebo. Postprandial plasma concentrations of the gut-derived incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 were increased after atorvastatin treatment compared with placebo. Also, postprandial concentrations of taurine-conjugated primary bile acids increased, whereas glycine-conjugated secondary bile acids decreased. Microbiota composition was not affected by atorvastatin treatment.
Conclusions:
Atorvastatin treatment did not alter glucose or insulin concentrations, nor did it alter gut microbiota composition. However, we found that atorvastatin treatment increased fasting and postprandial glucagon concentrations, which may point to hyperglucagonaemia as a possible link between statin treatment and type 2 diabetes.
Clinicaltrials.Gov:
NCT03018444.
Significance Statement:
This randomised, placebo-controlled, double-blind, crossover study reveals that short-term high-dose atorvastatin treatment increases fasting and postprandial glucagon levels and alters amino acid and bile acid profiles without affecting glucose, insulin, or gut microbiota in healthy men. These findings suggest hyperglucagonaemia as a potential mechanistic contributor to the increased risk of type 2 diabetes associated with statin therapy.
Insights
Atorvastatin increases glucagon levels, potentially linking statin use to type 2 diabetes risk. This study found no effect on glucose, insulin, or gut microbiota in healthy men.
Area of Science:
- Endocrinology
- Metabolic Disease
- Pharmacology
Background:
- Statins effectively lower LDL cholesterol and prevent cardiovascular events.
- Emerging evidence suggests statin therapy may increase type 2 diabetes risk.
- The underlying mechanisms for this association remain unclear.
Purpose of the Study:
- To investigate the effects of atorvastatin on glucose regulation, incretin hormones, bile acids, and gut microbiota.
- To explore potential mechanisms linking statin use to type 2 diabetes.
Main Methods:
- A randomized, placebo-controlled, double-blind, crossover study involving 15 healthy men.
- Participants received atorvastatin (40-80 mg/day) or placebo for 14 days.
- Measurements included fasting and postprandial glucose, glucoregulatory hormones, bile acids, and gut microbiota.
Main Results:
- Atorvastatin increased fasting and postprandial glucagon concentrations compared to placebo.
- Postprandial incretin hormones (GIP, GLP-1) and primary bile acids increased.
- No significant changes were observed in glucose, insulin, or gut microbiota composition.
Conclusions:
- Atorvastatin treatment increased glucagon levels, suggesting hyperglucagonaemia as a potential mechanism for increased type 2 diabetes risk.
- Short-term high-dose atorvastatin alters bile acid profiles but does not impact glucose, insulin, or gut microbiota in healthy individuals.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:18Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:16Hepatic Drug Excretion: Influencing Factors